NanoViricides, Inc. elaborated on its current assets and plans towards becoming a successful pharmaceutical company intending to revolutionize the treatment of viral infections. NV-387, lead broad-spectrum antiviral drug candidate has completed Phase I clinical trial in healthy subjects with no drop-outs and no reported adverse events, indicative of excellent safety and tolerability in humans. This single drug, NV-387, has been found to be highly active against a number of different types of viruses.

In addition, plan on seeking non-dilutive funding for the development of drugs that are of interest foriodefense. The company have already demonstrated the ability to manufacture own drug candidates at several Kilograms scales in cGMP-compliant processes for clinical trials. campus comprises a multi-Kg scale cGMP-compliant manufacturing facility with Class 100 clean rooms. The company have demonstrated capabilities for manufacture of the drug substance, and thereafter formulate, fill-finish-and-package the drug products for clinical trials in this facility.

The company believe that existing manufacturing facility would be adequate for market entry of NV-387 for the pediatric patients segment when the drug is approved by the FDA. The company also have a drug in development against herpesviruses, NV-HHV-1, formulated as a skin cream, that company plan on advancing through clinical trials for regulatory approval as a topical treatment of Shingles/Chickenpox skinashes, HSV-1 "cold sores", as well as HSV-2 "genital ulcers". NV-HHV-1 had completed IND-enabling studies by October 2019 just before the COVID-19 pandemic broke out, whereupon the company took up the challenge of developing a highly effective drug to treat all coronavirus infections.

The company believe these developments will continue to provide additional drug candidates to feed pipeline for several years to come. Thus, the company believe that the company are on the verge of substantial success and expansive growth in the near future: having successfully completed Phase I of first drug candidate, having amassed substantial data demonstrating superior antiviral activity of drug candidates in animal models, and now being poised to enter into Phase II human clinical trials.